TreatSMA reaches out to Roche

TreatSMA visited Roche yesterday to talk about Risdiplam and how we can support them through the approval and appraisal process.

Lucy, Gary, Joseph and Andi visited the Roche headquarters in Welwyn Garden City yesterday to meet with the team developing treatments for SMA, including Risdiplam. The purpose of the meeting was to introduce ourselves to Roche and talk to them about what TreatSMA has done in the past and how we can perhaps support Roche with the approval and appraisal process for Risdiplam.

It was a great discussion, and both sides benefited. It’s very early days in the development of Risdiplam, you can see from the picture below the current status of all trials. However both teams committed to staying in touch and continuing to develop a relationship to support upcoming processes.

Click here to download the above

TreatSMA Team

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more